Genmab A/S (OTCMKTS:GNMSF – Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $236.45 and last traded at $237.52, with a volume of 1109 shares changing hands. The stock had previously closed at $264.35.
Genmab A/S Trading Down 10.1 %
The firm has a market cap of $15.53 billion, a P/E ratio of 19.66 and a beta of 1.07. The firm has a 50-day simple moving average of $268.95 and a 200-day simple moving average of $276.85.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.13 EPS for the quarter. Genmab A/S had a return on equity of 20.60% and a net margin of 29.06%. The firm had revenue of $779.50 million during the quarter.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
- Five stocks we like better than Genmab A/S
- Investing In Automotive Stocks
- The Average 401k Balance by Age Explained
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What Are the U.K. Market Holidays? How to Invest and Trade
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
